Parallel Industries Inc.

Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products. The company was formerly known as Easton Pharmaceuticals Inc. and changed its name to Parallel Industries Inc. in December 2020. Parallel Industries Inc. was founded in 1997 and is headquartered in Toronto, Canada.

Parallel Industries Inc. trades as EAPH on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$189,000 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Parallel Industries Inc. can be compared against peers such as Advantis Corp., Black Bird Biotech, Inc., CannLabs, Inc., The Greater Cannabis Company, Inc., Green Rain Energy Holdings Inc., Panbela Therapeutics, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $18,655, beta of 27.13, and return on equity of -2.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EAPH currently shows total debt of $2.48M and beta of 27.13. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.eastonpharma.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.